Captopril and platelet-activating factor (PAF) antagonist prevent cardiac allograft vasculopathy in rats: Role of endogenous PAF and PAF-like compounds

Journal of Heart and Lung Transplantation

Volumn 18, Issue 5, 1999, Pages 470-477

  Crawford, Susan E ^a   Huang, Lijun ^a   Hsueh, Wei ^a   Takami, Hiroshi ^a   Gonzalez Crussi, Frank ^a   Backer, Carl L ^a   Mu, Yan ^a   Liu, Hanping ^a   Mavroudis, Constantine ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APAFANT; CAPTOPRIL; PHOSPHOLIPASE A2; PHOSPHOLIPID; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HEART TRANSPLANTATION; HISTOPATHOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; VASCULAR DISEASE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; AZEPINES; CAPTOPRIL; CORONARY DISEASE; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; HEART TRANSPLANTATION; MALE; PLATELET ACTIVATING FACTOR; PLATELET AGGREGATION INHIBITORS; RANDOM ALLOCATION; RATS; RATS, INBRED F344; RATS, INBRED LEW; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; TRIAZOLES; VENTRICULAR REMODELING;

EID: 0032990593     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-2498(98)00073-4     Document Type: Article

References (47)

1. Gao S.Z., Schroeder J.S., Alderman E.L., et al. Clinical and laboratory correlated coronary artery disease in the cardiac transplant patient. Circulation. 76:(suppl. V):1987;V56-V61.
2. Uretsky B.F., Murali S., Reddy P.S., et al. Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone. Circulation. 76:1987;827-834.
3. Kriett J., Kaye M.P. The registry of the International Society for Heart Transplantation seventh official report - 1990 . J Heart Transplant. 9:1990;323-330.
4. Hosenpud J.D., Shipley G.D., Wagner C.R. Cardiac allograft vasculopathy current concepts, recent developments, and future directions . J Heart Lung Transplant. 11:1992;9-23.
5. Backer C.L., Zales V.R., Idriss F.S., et al. Heart transplantation in neonates and in children. J Heart Lung Transplant. 11:1992;311-319.
6. Billingham M.E. Histopathology of graft coronary disease. J Heart Lung Transplant. 11:1992;S38-S44.
7. Naftilan A.J., Pratt R.E., Dzau V.J. Induction of platelet-derived growth factor A-chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells. J Clin Invest. 83:1989;1419-1424.
8. Bell L., Madri J.A. Influence of the angiotensin system on endothelial and smooth muscle cell migration. Am J Pathol. 137:1990;7-12.
9. 1 expression determines growth response to angiotensin II. J Clin Invest. 90:1992;456-461.
10. Molloy C.J., Taylor D.S., Weber H. Angiotensin II stimulation of rapid protein tyrosine phosphorylation and protein kinase activation in rat aortic smooth muscle cells. J Biol Chem. 268:1993;7338-7345.
11. Powell J.S., Clozel J.-P., Müller R.K., et al. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science. 245:1989;186-188.
12. Kobayashi J., Crawford S.E., Backer C.L., et al. Captopril reduces graft coronary artery disease in a rat heterotopic transplant model. Circulation. 88:(5 pt. 2):1993;I1286-I1290.
13. Beneviste J. Biological membranes aberrations in membrane structure and function: PAF-acether, an ether phospholipid with biological activity . 1988;73-85 Alan R. Liss, New York.
14. Hanahan D.J. Platelet activating factor a biologically active phosphoglyceride . Annu Rev Biochem. 55:1986;483-509.
15. Camussi G., Aglietta M., Coda R., Bussolino F., Biacibello W., Tetta C. Release of platelet-activating factor (PAF) and histamine. II. The cellular origin of human PAF monocytes, polymorphonuclear neutrophils and basophils . Immunol. 42:1981;191-199.
16. 2 in cultured rat mesangial cells. Am J Physiol. 253:1987;C113-C120.
17. Adams D.H., Tilney N.L., Collins J.J. Jr, Karnovsky M.J. Experimental graft arteriosclerosis. I. The Lewis-to-F-344 allograft model. Transplantation. 53:1992;1115-1119.
18. Ono K., Lindsey E.S. Improved technique of heart transplantation in rats. J Thorac Cardiovasc Surg. 57:1969;225-229.
19. Hsueh W., Gonzalez-Crussi F., Arroyave J.L. Platelet-activating factor an endogenous mediator for bowel necrosis in endotoxemia . FASEB J. 1:1987;403-405.
20. Clay K.L., Johnson C., Worthen G.S. Biosynthesis of platelet activating factor and 1-0-acyl analogues by endothelial cells. Biochimica et Biophysica Acta. 1094:1991;43-50.
21. Whatley R.E., Clay K.L., Chilton F.H., et al. Relative amounts of 1-O-alkyl- and 1-acyl-2-acetel-sn-glycero-3-phosphocholine in stimulated endothelial cells. Prostaglandins. 43:1992;21-29.
22. O'Flaherty J.T., Jacobson D.P., Redman J.F. Regulation of platelet-activating factor receptors and the desensitization response in polymorphonuclear neutrophils. Biochem J. 288:(pt. 1):1992;241-248.
23. Penit J., Faure M., Jard S. Vasopressin and angiotensin II receptors in rat aortic smooth muscle cells in culture. Am J Physiol. 244:1983;E72-E82.
24. Rakugi H., Jacob H.J., Krieger J.E., Ingelfinger J.R., Pratt R.E. Vascular injury induces angiotensin gene expression in the media and neointima. Circulation. 87:1993;283-290.
25. Caldwell P.R.B., Seegal B.C., Hsu K.C. Angiotensin-converting enzyme vascular endothelial localization . Science. 191:1976;1050-1051.
26. Yamada H., Fabris B., Allen A.M., Jackson B., Johnston C.I., Mendelsohn F.A.O. Localization of angiotensin converting enzyme in rat heart. Circ Res. 68:1991;141-149.
27. Mehra M.R., Ventura H.O., Chambers R., et al. Predictive model to assess risk for cardiac allograft vasculopathy an intravascular ultrasound study . J Am College of Cardiol. 26:1995;1537-1544.
28. Klahr S., Morrissey J. Angiotensin II and gene expression in the kidney. Am J Kidney Dis. 31:1998;171-176.
29. Perico N., Lapinski R., Konopka K., Aiello S., Noris M., Remuzzi G. Platelet-activating factor mediates angiotensin II-induced proteinuria in isolated perfused rat kidney. J Am Soc Nephrol. 8:1997;1391-1398.
30. Sugimoto T., Tsuchimochi H., McGregor C.G., Mutoh H., Shimizu T., Kurachi Y. Molecular cloning and characterization of the platelet-activating factor receptor gene expressed in the human heart. Biochem Biophys Res Commun. 189:1992;617-624.
31. Ito S., Camussi G., Tetta C., Milgrom F., Andres G. Hyperacute renal allograft rejection in the rabbit. The role of platelet-activating factor and of cationic proteins derived from polymorphonuclear leukocytes and from platelets. Lab Invest. 44:1984;148-161.
32. Camussi G., Aglietta M., Malavasi F., et al. The release of platelet-activating factor from human endothelial cells in culture. J Immunol. 131:1983;2397-2403.
33. Rainger G.E., Fisher A.C., Nash G.B. Endothelial-borne platelet-activating factor and interleukin-8 rapidly immobilize rolling neutrophils. Am J Physiol. 272:(1 pt. 2):1997;H114-H122.
34. Salomon R.N., Hughes C.C.W., Schoen F.J., Payne D.D., Pober J.S., Libby P. Human coronary transplantation-associated arteriosclerosis. Am J Pathol. 138:1991;791-798.
35. Makowka L., Chapman F.A., Cramer D.V., Qian S., Sun H., Starzl T.E. Platelet-activating factor and hyperacute rejection. Transplantation. 50:1990;359-365.
36. Freiche J.-C.A., Lang J., Sedivy P., Touraine J.-L. Prolonged survival of renal transplants in nonimmunized and hyperimmunized rats receiving a platelet-activating factor antagonist. Transplantation. 50:1990;8-13.
37. Foegh M.L., Khirabadi B.S., Rowles J.R., Braquet P., Ramwell P.W. Prolongation of cardiac allograft survival with BN 52021, a specific antagonist of platelet-activating factor. Transplantation. 42:1986;86-88.
38. Mueller H.W., Haught C.A., McNatt J.M., et al. Measurement of platelet-activating factor in a canine model of coronary thrombosis and in endarterectomy samples from patients with advanced coronary artery disease. Circ Res. 77:1995;54-63.
39. Feuerstein G., Rabinovici R., Leor J., Winkler J.D., Vonhof S. Platelet-activating factor and cardiac diseases therapeutic potential for PAF inhibitors . J Lipid Mediat Cell Signal. 15:1997;255-284.
40. Daeman M.J.A.P., Lombardi D.M., Bosman F.T., Schwartz S.M. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res. 68:1991;450-456.
41. Yokoshiki H., Kohya T., Tomita F., et al. Restoration of action potential duration and transient outward current by regression of left ventricular hypertrophy. J Mol Cell Cardiol. 29:1997;1331-1339.
42. Rials S.J., Wu Y., Xu X., Filart R.A., Marinchak R.A., Kowey P.R. Regression of left ventricular hypertrophy with captopril restores normal ventricular action potential duration, dispersion of refractoriness, and vulnerability to inducible ventricular fibrillation. Circulation. 96:1997;1330-1336.
43. Crawford S.E., Huang L.J., Mu Y., Backer C.L., Pahl E., Gidding S.S., Mavroudis C. Captopril selectively restores TGF-β1 Type II/Type I receptor ratio to pre-transplantation levels in rat allograft coronary vessels. (abstract) J Heart Lung Transplant. 17:1998;61.
44. Crawford S.E., Mu Y., Huang L.J., et al. Rat allograft coronary vessels switch to secreting angiogenic proteins post transplantation: possible therapeutic role of platelet-activating factor (PAF) antagonist (abstract). Seventeenth annual meeting of the American Society of Transplant Physicians. Transplantation. 65:1998;116.
45. Takahashi N., Calderone A., Izzo N.J. Jr, Maki T.M., Marsh J.D., Colucci W.S. Hypertrophic stimuli induce transforming growth factor-beta 1 expression in rat ventricular myocytes. J Clin Invest. 94:1994;1470-1476.
46. Brand T., Schneider M.D. The TGF beta superfamily in myocardium ligands, receptors, transduction, and function . J Mol Cell Cardiol. 27:1995;5-18.
47. Brooks W.W., Bing O.H., Conrad C.H., et al. Captopril modifies expression in hypertrophied and failing hearts of aged spontaneously hypertensive rats. Hypertension. 30:1997;1362-1368.